tetano
Editor, Senior Moderator
Nat Commun
. 2021 Feb 19;12(1):1152.
doi: 10.1038/s41467-021-20973-3.
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
Matthias Becker[SUP] #[/SUP][SUP] 1 [/SUP], Monika Strengert[SUP] #[/SUP][SUP] 2 3 [/SUP], Daniel Junker[SUP] 1 [/SUP], Philipp D Kaiser[SUP] 1 [/SUP], Tobias Kerrinnes[SUP] 4 [/SUP], Bjoern Traenkle[SUP] 1 5 [/SUP], Heiko Dinter[SUP] 1 5 [/SUP], Julia H?ring[SUP] 1 [/SUP], St?phane Ghozzi[SUP] 2 [/SUP], Anne Zeck[SUP] 1 [/SUP], Frank Weise[SUP] 1 [/SUP], Andreas Peter[SUP] 6 7 8 [/SUP], Sebastian H?rber[SUP] 6 7 8 [/SUP], Simon Fink[SUP] 1 [/SUP], Felix Ruoff[SUP] 1 [/SUP], Alex Dulovic[SUP] 1 [/SUP], Tamam Bakchoul[SUP] 9 [/SUP], Armin Baillot[SUP] 10 [/SUP], Stefan Lohse[SUP] 11 [/SUP], Markus Cornberg[SUP] 12 [/SUP], Thomas Illig[SUP] 13 [/SUP], Jens Gottlieb[SUP] 14 15 [/SUP], Sigrun Smola[SUP] 11 [/SUP], Andr? Karch[SUP] 16 [/SUP], Klaus Berger[SUP] 16 [/SUP], Hans-Georg Rammensee[SUP] 17 18 19 [/SUP], Katja Schenke-Layland[SUP] 1 19 20 21 [/SUP], Annika Nelde[SUP] 17 19 22 [/SUP], Melanie M?rklin[SUP] 19 21 [/SUP], Jonas S Heitmann[SUP] 19 21 [/SUP], Juliane S Walz[SUP] 17 19 22 23 [/SUP], Markus Templin[SUP] 1 [/SUP], Thomas O Joos[SUP] 1 [/SUP], Ulrich Rothbauer[SUP] #[/SUP][SUP] 1 5 [/SUP], G?rard Krause[SUP] 2 3 [/SUP], Nicole Schneiderhan-Marra[SUP] 24 [/SUP]
Affiliations
Abstract
The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.
. 2021 Feb 19;12(1):1152.
doi: 10.1038/s41467-021-20973-3.
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
Matthias Becker[SUP] #[/SUP][SUP] 1 [/SUP], Monika Strengert[SUP] #[/SUP][SUP] 2 3 [/SUP], Daniel Junker[SUP] 1 [/SUP], Philipp D Kaiser[SUP] 1 [/SUP], Tobias Kerrinnes[SUP] 4 [/SUP], Bjoern Traenkle[SUP] 1 5 [/SUP], Heiko Dinter[SUP] 1 5 [/SUP], Julia H?ring[SUP] 1 [/SUP], St?phane Ghozzi[SUP] 2 [/SUP], Anne Zeck[SUP] 1 [/SUP], Frank Weise[SUP] 1 [/SUP], Andreas Peter[SUP] 6 7 8 [/SUP], Sebastian H?rber[SUP] 6 7 8 [/SUP], Simon Fink[SUP] 1 [/SUP], Felix Ruoff[SUP] 1 [/SUP], Alex Dulovic[SUP] 1 [/SUP], Tamam Bakchoul[SUP] 9 [/SUP], Armin Baillot[SUP] 10 [/SUP], Stefan Lohse[SUP] 11 [/SUP], Markus Cornberg[SUP] 12 [/SUP], Thomas Illig[SUP] 13 [/SUP], Jens Gottlieb[SUP] 14 15 [/SUP], Sigrun Smola[SUP] 11 [/SUP], Andr? Karch[SUP] 16 [/SUP], Klaus Berger[SUP] 16 [/SUP], Hans-Georg Rammensee[SUP] 17 18 19 [/SUP], Katja Schenke-Layland[SUP] 1 19 20 21 [/SUP], Annika Nelde[SUP] 17 19 22 [/SUP], Melanie M?rklin[SUP] 19 21 [/SUP], Jonas S Heitmann[SUP] 19 21 [/SUP], Juliane S Walz[SUP] 17 19 22 23 [/SUP], Markus Templin[SUP] 1 [/SUP], Thomas O Joos[SUP] 1 [/SUP], Ulrich Rothbauer[SUP] #[/SUP][SUP] 1 5 [/SUP], G?rard Krause[SUP] 2 3 [/SUP], Nicole Schneiderhan-Marra[SUP] 24 [/SUP]
Affiliations
- PMID: 33608538
- DOI: 10.1038/s41467-021-20973-3
Abstract
The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.